RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been given a consensus recommendation of “Hold” by the nine research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $4.00.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of RAPT Therapeutics in a research report on Monday, March 10th.

Institutional Trading of RAPT Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Medicxi Ventures Management Jersey Ltd purchased a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $35,316,000. TCG Crossover Management LLC acquired a new position in RAPT Therapeutics in the 4th quarter valued at about $19,751,000. Orbimed Advisors LLC purchased a new stake in shares of RAPT Therapeutics in the 4th quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC acquired a new stake in shares of RAPT Therapeutics during the 4th quarter worth approximately $19,750,000. Finally, RTW Investments LP purchased a new stake in shares of RAPT Therapeutics during the 4th quarter valued at approximately $18,587,000. 99.09% of the stock is owned by institutional investors and hedge funds.

RAPT Therapeutics Stock Down 1.3 %

RAPT opened at $0.79 on Monday. The firm’s fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $1.35. RAPT Therapeutics has a 52-week low of $0.75 and a 52-week high of $8.58. The company has a market cap of $104.35 million, a price-to-earnings ratio of -0.29 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, research analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.